Protamine Use During Chronic Total Occlusion Percutaneous Coronary Intervention: A Multicenter Registry
Catheterization and Cardiovascular Interventions · 2026-03 · 107 (4) · 1254-1266
DOI: 10.1002/ccd.70472 ↗At a glance
Multizentrische Studie in Catheterization and Cardiovascular Interventions, published online on 2026-01-11. Written by Sant Kumar and 13 co-authors. Institution: Department of Medicine, Division of Cardiology, University of Washington, Seattle, Washington, USA. Major MEDLINE topics: Protamines, Coronary Occlusion, Percutaneous Coronary Intervention, Heparin Antagonists. 18 references.
Abstract (original language)
Background
The safety and efficacy of protamine reversal of heparin anticoagulation during chronic total occlusion (CTO) percutaneous coronary intervention (PCI) is unknown. To outline the indications for and outcomes of protamine administration during CTO PCI.
Methods
We conducted a multicenter registry of consecutive patients who underwent CTO PCI between January 2019 and March 2025 at five centers and received protamine. Patients were stratified into bailout (for perforation or access‐site bleeding) and non‐bailout cohorts. The primary endpoint was major adverse cardiovascular events (all‐cause death, myocardial infarction, target vessel revascularization, and pericardiocentesis). Outcomes were reported descriptively by indication for protamine use, without formal comparative analysis.
Results
Among 2345 CTO PCI procedures, 672 patients (28.7%) received protamine, including 179 in the bailout cohort and 493 in the non‐bailout cohort. The mean J‐CTO score was 3.0 ± 1.3 in the bailout cohort and 2.6 ± 1.2 in the non‐bailout cohort. Retrograde strategies were used in 31.8% of the bailout cohort and 19.3% of the non‐bailout cohort. Overall, there were 126 coronary perforations observed (6.1%), of which 10 cases (0.5%) required pericardiocentesis. In‐hospital major adverse cardiovascular events occurred in 20 patients (11.2%) in the bailout cohort and in 10 patients (2.0%) in the non‐bailout cohort (reported descriptively without comparative inference). Across both cohorts, there were no reported cases of stent thrombosis or anaphylaxis.
Conclusion
Protamine use during CTO PCI was variably applied across centers and was associated with acceptable in‐hospital outcomes; however, the lack of a non‐protamine comparison group limits any inference regarding safety.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medicine, Division of Cardiology, University of Washington, Seattle, Washington, USA.
- Department of Cardiology, Creighton University School of Medicine, Phoenix, Arizona, USA.
- Division of Cardiology, Wellspan Health, York, Pennsylvania, USA.
- The Christ Hospital Heart and Vascular Institute, Cincinnati, Ohio, USA.
- Massachusetts General Hospital, Mass General Brigham, Boston, Massachusetts, USA.
- Virginia Heart, Inova Schar Heart and Vascular Institute, Fairfax, Virginia, USA.
ORCID profiles: Sant Kumar, Alexander G Truesdell, Lorenzo Azzalini
Cite
APA
Kumar, S., Roomi, S. S., Muuse, J., Wong, A., Boudreau, R., Jamil, Y., Kearney, K. E., Lombardi, W. L., Jaffer, F., Frizzell, J., Cilia, L., Davies, R. E., Truesdell, A. G., & Azzalini, L. (2026). Protamine Use During Chronic Total Occlusion Percutaneous Coronary Intervention: A Multicenter Registry. Catheterization and Cardiovascular Interventions, 107(4), 1254-1266. https://doi.org/10.1002/ccd.70472
Vancouver
Kumar S, Roomi SS, Muuse J, Wong A, Boudreau R, Jamil Y, et al. Protamine Use During Chronic Total Occlusion Percutaneous Coronary Intervention: A Multicenter Registry. Catheterization and Cardiovascular Interventions. 2026;107(4):1254-1266. doi:10.1002/ccd.70472
BibTeX
@article{Kumar2026,
author = {Kumar, Sant and Roomi, Sohaib S and Muuse, Janelle and Wong, Alan and Boudreau, Rene and Jamil, Yasser and Kearney, Kathleen E and Lombardi, William L and Jaffer, Farouc and Frizzell, Jarrod and Cilia, Lindsey and Davies, Rhian E and Truesdell, Alexander G and Azzalini, Lorenzo},
title = {Protamine Use During Chronic Total Occlusion Percutaneous Coronary Intervention: A Multicenter Registry},
journal = {Catheterization and Cardiovascular Interventions},
year = {2026},
volume = {107},
number = {4},
pages = {1254--1266},
doi = {10.1002/ccd.70472}
}
EUVIMED